Relapsed/refractory multiple myeloma is disease that progresses on salvage therapy or within 60 days of the last treatment in patients who in the past experienced at least a minimal response to treatment. Primary refractory multiple myeloma, however, is disease that fails to achieve at least a minimal response with any therapy.
Progressive multiple myeloma is defined as a 25% increase from baseline in serum M protein (absolute increase > 0.5 g/dL), urine M protein (absolute increase ≥ 200 mg/d); percentage of bone marrow plasma cells (absolute percentage increase ≥ 10%); and/or the difference between involved and uninvolved free light chain levels (absolute increase ≥ 10 mg/dL). Progressive disease may also be noted upon development of definite new bone lesions and/or soft-tissue plasmacytomas (with a clear increase in the size of existing plasmacytomas), or hypercalcemia that cannot be attributed to another cause.
Learn more about multiple myeloma.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maria-Victoria Mateos. Fast Five Quiz: Relapsed/Refractory Multiple Myeloma - Medscape - Jan 11, 2022.